The Peptide That Outperformed Hydroquinone — and Why Australia Banned It

Most brightening products target one enzyme. That is like trying to control a flood by blocking a single pipe when the problem is the pump.

The pump, in the case of pigmentation, is a transcription factor called MITF. It is the master switch that controls the production of every enzyme involved in melanin synthesis. If MITF is active, pigmentation proceeds. If MITF is suppressed, the entire melanogenic cascade slows down at its source.

This is the mechanism behind Oligopeptide-68, the lead active in the Revitalize Brightening Serum. And it is why Dr Alison Jamieson selected it over simpler, single-pathway alternatives.

The Problem With Targeting One Enzyme

For decades, the gold standard for treating hyperpigmentation was hydroquinone. It works by inhibiting tyrosinase, the enzyme responsible for converting tyrosine into melanin. Effective at that one job. But tyrosinase is only one of several enzymes in the pigmentation pathway. And hydroquinone comes with a significant safety profile.

Prolonged use of hydroquinone can cause ochronosis — a paradoxical, irreversible darkening of the skin. The risk was serious enough that hydroquinone is now banned for over-the-counter sale in Australia, the European Union, and Japan. If you are using it, you need a prescription and close medical supervision.

The question Dr Jamieson asked was straightforward: is there an ingredient that addresses pigmentation at a more fundamental level, with clinical evidence to support it, and without those risks?

Oligopeptide-68: Targeting the Master Switch

Oligopeptide-68 is a synthetic peptide designed to mimic TGF-β, a signalling protein involved in cellular regulation. Its specific action in the context of pigmentation is to downregulate MITF — the master transcription factor that sits upstream of every melanogenic enzyme.

Think of it this way. Tyrosinase is one worker on the production line. MITF is the foreman who decides whether the entire factory operates. Suppress the foreman, and the whole line slows down. That is what Oligopeptide-68 does.

This is not a theoretical mechanism. It was tested in a randomised, double-blind clinical trial published by Pratchyapurit in 2016. Thirty-eight patients with hyperpigmentation were randomised to receive either an Oligopeptide-68 formulation or hydroquinone at 2% and 4% concentrations. The trial ran for 12 weeks.

The results were notable. The Oligopeptide-68 formulation matched or outperformed hydroquinone across all concentrations tested. 76.3% of participants in the peptide group showed moderate improvement or better. No severe adverse reactions were reported.

To be clear about what that means: a peptide with no known ochronosis risk performed as well as a drug that is banned over the counter in three major regulatory jurisdictions. That is a meaningful clinical finding.

Why One Active Is Not Enough

Dr Jamieson does not formulate around a single ingredient, regardless of how compelling its data is. Pigmentation is a multi-stage biological process, and an effective intervention needs to address each stage.

The Revitalize Brightening Serum targets all five stages of the pigmentation cascade:

Stage 1 — The master switch. Oligopeptide-68 downregulates MITF, reducing the signal that activates all downstream melanogenic enzymes.

Stage 2 — The enzyme. Vitamin C and licorice root extract both inhibit tyrosinase directly. Licorice root is worth particular attention here. Research published in 2025 confirmed that it targets MITF through the CREB/CRTC1 pathway, and in vitro testing demonstrated 16 times greater tyrosinase inhibition than hydroquinone. Sixteen times.

Stage 3 — The transfer. Once melanin is produced, it must be transferred from melanocytes to surrounding keratinocytes. Niacinamide blocks this transfer by 35 to 68%, depending on concentration. The melanin is produced, but it does not reach the visible surface of your skin.

Stage 4 — Cell turnover. An AHA blend accelerates the natural shedding of pigmented surface cells, revealing newer, more evenly toned skin beneath.

Stage 5 — The oxidative trigger. UV exposure and oxidative stress are primary triggers of melanin production. Ascorbic acid neutralises the free radicals that initiate the signalling cascade in the first place.

Five stages. Five mechanisms. Each one supported by a different active, and each one reinforcing the others.

The Ingredient Australia Banned — and What Replaced It

It is worth pausing on why hydroquinone was banned in Australia. The decision was not made lightly. Hydroquinone is effective at inhibiting tyrosinase. But with prolonged use, particularly at higher concentrations, it can cause permanent damage to the very skin it was meant to treat.

Ochronosis presents as blue-black deposits in the dermis. It is disfiguring, difficult to treat, and irreversible. The regulatory bodies in Australia, the EU, and Japan concluded that the risk-benefit ratio for unsupervised, over-the-counter use was not acceptable.

This created a genuine clinical need: patients with hyperpigmentation still required effective treatment, but needed options without those risks. Oligopeptide-68 and the broader multi-pathway approach used in the Brightening Serum represent one answer to that need. The clinical evidence suggests it is a well-supported one.

Where This Fits in The Protocol

The Revitalize Brightening Serum is a PM Protocol step, applied in the evening when skin is in its natural repair and renewal phase. This timing is deliberate. Cell turnover is highest during sleep, which means the AHA blend and the active peptide complex work alongside your skin's own biological clock, not against it.

But addressing pigmentation in the evening is only half the equation. If you are treating hyperpigmentation without protecting your skin from UV during the day, you are refilling the bucket while trying to empty it.

This is why Dr Jamieson considers the Revitalize Anti-Ageing Day Cream SPF 15 an essential companion for anyone using the Brightening Serum. The PM Protocol suppresses pigmentation production and clears existing deposits. The AM Protocol prevents new pigmentation from forming in the first place. The two work as a system.

That is the principle behind every protocol Dr Jamieson designs: no product works in isolation. Each step supports the others, and the results compound over consistent, daily use.

Choosing the Source, Not the Symptom

There are many brightening products available. Most of them target a single downstream enzyme and hope for the best. Some of them work. But they are, by design, addressing a symptom rather than a source.

Oligopeptide-68 targets MITF — the single transcription factor that governs the entire melanogenic system. When you suppress the master switch, you do not need to chase every individual enzyme downstream. The system quiets itself.

Dr Jamieson formulates for this kind of logic. Not the most exciting ingredient, but the most precise one. Not the loudest claim, but the most defensible one. And always within the context of a protocol that addresses the full biological picture, not a fragment of it.

⚕️ Note: Clinical data referenced in this article is from the Pratchyapurit 2016 randomised, double-blind trial (n=38, 12 weeks). In vitro comparisons (licorice root vs hydroquinone) reflect laboratory findings and may not directly translate to clinical outcomes. Individual results vary. Consult your prescribing doctor for personalised advice.

Dr Alison Jamieson — MBBS, FRACGP, Dip Derm — formulates all Aliangé products based on over 40 years of clinical experience treating Australian skin.